- Could You Spot the Silent Symptoms of Stress?
- Gas Stoves Could Leave Your Lungs Vulnerable to Nitrogen Dioxide
- Key Therapy Equally Effective for Women, Men With Narrowed Leg Arteries
- Doctors Describe Texas Dairy Farm Worker’s Case of Bird Flu
- Does Preschool Boost Kids’ Long-Term Academic Success? Study Finds Mixed Results
- AI Might Spot Rare Diseases in Patients Years Earlier
- An Orangutan Healed Himself With Medicinal Plant
- Quit-Smoking Meds Not Working for You? Try Upping the Dose
- Fewer Americans Are Suffering Most Dangerous Form of Heart Attack
- Even Skipping Meat for One Meal Helps Liver Disease Patients
New Treatment for Anthrax Approved
A new treatment to prepare the United States for the potential release of deadly inhalational anthrax has been approved by the U.S. Food and Drug Administration.
Anthrasil (Anthrax Immune Globulin Intravenous) is sanctioned, when combined with approved antibiotics, to support the nation’s preparedness against a possible anthrax attack, the FDA said Wednesday in a news release. Other rare but possible means of human exposure to the deadly bacteria include infected animals or contaminated animal products.
Anthrasil is made from the plasma of people who have been vaccinated against anthrax. The plasma includes antibodies that neutralize poisons produced by anthrax, the FDA said. The drug will be stored in the U.S. Strategic National Stockpile for use in an “anthrax emergency,” the agency said.
Because it wasn’t “feasible or ethical” to expose people to anthrax, Anthrasil’s effectiveness was tested in rabbits and monkeys, the agency said. The vaccine’s safety was evaluated among 74 healthy people who weren’t exposed to anthrax. The most common side effects included headache, back pain, nausea, pain at the injection site and swelling.
Anthrasil is produced by Cangene Corp., based in Winnipeg, Canada.
More information
Visit the FDA to learn more.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.